Edwards Lifesciences Corporation $EW Shares Sold by Rathbones Group PLC

Rathbones Group PLC trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 81.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 16,695 shares of the medical research company’s stock after selling 71,276 shares during the quarter. Rathbones Group PLC’s holdings in Edwards Lifesciences were worth $1,423,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after purchasing an additional 365,581 shares in the last quarter. Wellington Management Group LLP lifted its stake in Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after buying an additional 977,933 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the last quarter. Jennison Associates LLC lifted its stake in Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,968 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $82.07, for a total transaction of $818,073.76. Following the completion of the sale, the vice president owned 22,798 shares in the company, valued at $1,871,031.86. This represents a 30.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the sale, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This trade represents a 1.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 106,684 shares of company stock worth $8,811,739 over the last 90 days. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $85.93 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The business has a 50 day simple moving average of $81.42 and a 200-day simple moving average of $82.89. The stock has a market capitalization of $49.48 billion, a PE ratio of 45.71, a price-to-earnings-growth ratio of 2.09 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the prior year, the business earned $0.64 earnings per share. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on EW shares. Wells Fargo & Company boosted their price objective on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. UBS Group reiterated a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.65.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.